Clinical characteristics of patient cohort with relapsed/refractory CLL treated with venetoclax (n = 89)
| Clinical characteristic . | Cohort (n = 89) . |
|---|---|
| Median age at venetoclax initiation, years (range) | 67 (45-87) |
| Male:Female | 71:18 |
| Median number of prior therapies (range) | 3 (0-12) |
| Prior fludarabine-combination therapy exposure | 72 (81%) |
| Del(17p) and/or TP53 mutation prior to venetoclax initiation (n/N, %) | 46/81 (57%) |
| Median duration on venetoclax, months (range) | 29 (1-98+) |
| Median survivor follow-up from venetoclax initiation, months (range) | 75 (21-98+) |
| Clinical characteristic . | Cohort (n = 89) . |
|---|---|
| Median age at venetoclax initiation, years (range) | 67 (45-87) |
| Male:Female | 71:18 |
| Median number of prior therapies (range) | 3 (0-12) |
| Prior fludarabine-combination therapy exposure | 72 (81%) |
| Del(17p) and/or TP53 mutation prior to venetoclax initiation (n/N, %) | 46/81 (57%) |
| Median duration on venetoclax, months (range) | 29 (1-98+) |
| Median survivor follow-up from venetoclax initiation, months (range) | 75 (21-98+) |